Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chronic Convection Enhanced Delivery of Topotecan for Recurrent High Grade Gliomas
NCT03154996Phase 1Completed
- Sponsor
- Columbia University
- Start
- Jan 2018
- Primary completion
- Aug 2021
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of topotecan liposome in glioma, sponsored by Columbia University. Primary endpoint: Dose at which all patients have had no greater than grade 2 adverse reactions up to 29 days. Started Jan 2018; status: completed.
02
Drugs
topotecan liposome
03
Conditions
glioma
Beyond the preview
Go deeper on NCT03154996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03154996.